Efficacy and Safety of Ketoprofen Patch in Patients With Rheumatoid Arthritis: A Randomized, Double-Blind, Placebo-Controlled Study

被引:12
作者
Kawai, Shinichi [1 ]
Uchida, Eiji [2 ]
Kondo, Masakazu [3 ]
Ohno, Syuji [4 ]
Obata, Junichi [5 ]
Nawata, Yasushi [6 ]
Sugimoto, Kazunori [7 ]
Oribe, Motohiro [8 ]
Nagaya, Ikuo [9 ]
机构
[1] Toho Univ, Sch Med, Div Rheumatol, Dept Internal Med,Ota Ku, Tokyo 1438541, Japan
[2] Showa Univ, Sch Med, Dept Pharmacol 2, Tokyo 142, Japan
[3] Kondo Clin Rheumatol & Orthopaed Surg, Fukuoka, Japan
[4] Ohno Clin, Saitama, Japan
[5] Hikarichuo Clin, Kanagawa, Japan
[6] Chibaken Saiseikai Narashino Hosp, Div Rheumatol & Clin Immunol, Chiba, Japan
[7] Fukui Gen Hosp, Div Rheumatol & Clin Immunol, Fukui, Japan
[8] Oribe Rheumatism & Internal Med Clin, Oita, Japan
[9] Aichi ARG Fdn, Aichi, Japan
关键词
Rheumatoid arthritis; nonsteroidal antiinflammatory drugs; clinical trial; CARDIOVASCULAR EVENTS; TOPICAL DICLOFENAC; KNEE; PAIN; OSTEOARTHRITIS; ABSORPTION; CELECOXIB; SEVERITY;
D O I
10.1177/0091270009355813
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
This study assessed the efficacy and safety of ketoprofen patch compared with placebo in patients who had rheumatoid arthritis and persistent wrist pain. Patients (N = 676) who had achieved systemic disease control with a disease-modifying antirheumatic drug and/or systemic corticosteroid, but still had persistent wrist pain, were randomized to a 2-week course of once-daily treatment with application of a 20-mg ketoprofen patch or a placebo patch to the wrist. The primary efficacy end point was the percent change from baseline to the end of treatment in the intensity of wrist pain scored by each patient on a 100-mm visual analog scale. The mean +/- SD percent change on the pain intensity scale was significantly larger in patients treated with ketoprofen than in those receiving placebo (31.2% +/- 30.3% [95% confidence interval: 28.0-34.4] vs 25.5% +/- 31.2% [95% confidence interval: 22.1-28.8]; P = .020). However, the actual difference of the mean pain intensity scale between the 2 groups was small at the end of treatment. The frequency of adverse events was similar in both groups. The ketoprofen patch was more effective than placebo for relieving persistent local joint pain in patients with rheumatoid arthritis. The patch was also safe and well tolerated during the 2-week treatment period.
引用
收藏
页码:1171 / 1179
页数:9
相关论文
共 27 条
[1]   THE AMERICAN-RHEUMATISM-ASSOCIATION 1987 REVISED CRITERIA FOR THE CLASSIFICATION OF RHEUMATOID-ARTHRITIS [J].
ARNETT, FC ;
EDWORTHY, SM ;
BLOCH, DA ;
MCSHANE, DJ ;
FRIES, JF ;
COOPER, NS ;
HEALEY, LA ;
KAPLAN, SR ;
LIANG, MH ;
LUTHRA, HS ;
MEDSGER, TA ;
MITCHELL, DM ;
NEUSTADT, DH ;
PINALS, RS ;
SCHALLER, JG ;
SHARP, JT ;
WILDER, RL ;
HUNDER, GG .
ARTHRITIS AND RHEUMATISM, 1988, 31 (03) :315-324
[2]   Clinically significant changes in pain along the visual analog scale [J].
Bird, SB ;
Dickson, EW .
ANNALS OF EMERGENCY MEDICINE, 2001, 38 (06) :639-643
[3]   Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial [J].
Bresalier, RS ;
Sandler, RS ;
Quan, H ;
Bolognese, JA ;
Oxenius, B ;
Horgan, K ;
Lines, C ;
Riddell, R ;
Morton, D ;
Lanas, A ;
Konstam, MA ;
Baron, JA .
NEW ENGLAND JOURNAL OF MEDICINE, 2005, 352 (11) :1092-1102
[4]  
Brühlmann P, 2003, CLIN EXP RHEUMATOL, V21, P193
[5]   Risk of cardiovascular events and celecoxib: a systematic review and meta-analysis [J].
Caldwell, B ;
Aldington, S ;
Weatherall, M ;
Shirtcliffe, P ;
Beasley, R .
JOURNAL OF THE ROYAL SOCIETY OF MEDICINE, 2006, 99 (03) :132-140
[6]   AMERICAN-COLLEGE-OF-RHEUMATOLOGY PRELIMINARY DEFINITION OF IMPROVEMENT IN RHEUMATOID-ARTHRITIS [J].
FELSON, DT ;
ANDERSON, JJ ;
BOERS, M ;
BOMBARDIER, C ;
FURST, D ;
GOLDSMITH, C ;
KATZ, LM ;
LIGHTFOOT, R ;
PAULUS, H ;
STRAND, V ;
TUGWELL, P ;
WEINBLATT, M ;
WILLIAMS, HJ ;
WOLFE, F ;
KIESZAK, S .
ARTHRITIS AND RHEUMATISM, 1995, 38 (06) :727-735
[7]   Prospective validation of clinically important changes in pain severity measured on a visual analog scale [J].
Gallagher, EJ ;
Liebman, M ;
Bijur, PE .
ANNALS OF EMERGENCY MEDICINE, 2001, 38 (06) :633-638
[8]   HUMAN CYCLOOXYGENASE-2 CDNA [J].
HLA, T ;
NEILSON, K .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1992, 89 (16) :7384-7388
[9]  
Kawai Shinichi, 2003, J Orthop Sci, V8, P259, DOI 10.1007/s007760300045
[10]  
Kawail S., 2005, Allergology International, V54, P209, DOI [10.2332/ allergolint.54.209., DOI 10.2332/ALLERGOLINT.54.209]